Cargando…

Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection

BACKGROUND: Laparoscopic abdominal surgery is considered superior to open surgery. However, efficacy and safety outcomes of laparoscopic surgery in colorectal cancer (CRC) are unclear, particularly in patients undergoing antiplatelet therapy (APT). The aim of this study was to evaluate safety of ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimoto, Yasunori, Fujikawa, Takahisa, Tanaka, Akira, Hayashi, Hideto, Shimoike, Norihiro, Kawamoto, Hiroshi, Nakasuga, Chiyo, Yamamoto, Tsunenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545215/
https://www.ncbi.nlm.nih.gov/pubmed/31153382
http://dx.doi.org/10.1186/s12957-019-1634-4
_version_ 1783423354391232512
author Yoshimoto, Yasunori
Fujikawa, Takahisa
Tanaka, Akira
Hayashi, Hideto
Shimoike, Norihiro
Kawamoto, Hiroshi
Nakasuga, Chiyo
Yamamoto, Tsunenori
author_facet Yoshimoto, Yasunori
Fujikawa, Takahisa
Tanaka, Akira
Hayashi, Hideto
Shimoike, Norihiro
Kawamoto, Hiroshi
Nakasuga, Chiyo
Yamamoto, Tsunenori
author_sort Yoshimoto, Yasunori
collection PubMed
description BACKGROUND: Laparoscopic abdominal surgery is considered superior to open surgery. However, efficacy and safety outcomes of laparoscopic surgery in colorectal cancer (CRC) are unclear, particularly in patients undergoing antiplatelet therapy (APT). The aim of this study was to evaluate safety of antiplatelet agents, especially aspirin, in peri-operative management of patients undergoing laparoscopic colorectal resection for CRC. METHODS: A total of 578 radical laparoscopic colorectal surgeries in CRC patients performed between January 2005 and December 2015 at the Kokura Memorial Hospital were retrospectively reviewed. Patients were divided into three groups based on the risk for thromboembolism: a high-risk group receiving APT (APT-HR), a low-risk group receiving APT (APT-LR), and a low-risk group not receiving APT (non-APT). Bleeding complications (BC) and thromboembolic complications (TC) were assessed. Perioperative and outcome variables in groups receiving APT were compared with those in the non-APT group. RESULTS: APT-HR, APT-LR, and non-APT groups included 54 (9.3%), 114 (19.7%), and 410 (70.9%) patients, respectively. Blood loss during operation (p = 0.304), operative time (p = 0.956), hospitalisation after surgery (p = 0.307), and Clavien–Dindo classification of surgery-related complications (p = 0.467) were not significantly different in the three groups. Occurrence of intra-operative BC (blood loss ≥ 200 ml) (p = 0.864), post-operative BC (p = 0.630), and TC (p = 0.287) were also not significantly different in the three groups. Results of our analysis indicated that APT and non-interrupted APT were not associated with BC or TC. CONCLUSIONS: Analysis of laparoscopic colorectal resection in CRC showed that APT was not a major factor for fatal BC or TC. In patients with high thromboembolic risk, continuing aspirin may inhibit the increase in TC without increasing BC in the peri-operative period.
format Online
Article
Text
id pubmed-6545215
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65452152019-06-05 Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection Yoshimoto, Yasunori Fujikawa, Takahisa Tanaka, Akira Hayashi, Hideto Shimoike, Norihiro Kawamoto, Hiroshi Nakasuga, Chiyo Yamamoto, Tsunenori World J Surg Oncol Research BACKGROUND: Laparoscopic abdominal surgery is considered superior to open surgery. However, efficacy and safety outcomes of laparoscopic surgery in colorectal cancer (CRC) are unclear, particularly in patients undergoing antiplatelet therapy (APT). The aim of this study was to evaluate safety of antiplatelet agents, especially aspirin, in peri-operative management of patients undergoing laparoscopic colorectal resection for CRC. METHODS: A total of 578 radical laparoscopic colorectal surgeries in CRC patients performed between January 2005 and December 2015 at the Kokura Memorial Hospital were retrospectively reviewed. Patients were divided into three groups based on the risk for thromboembolism: a high-risk group receiving APT (APT-HR), a low-risk group receiving APT (APT-LR), and a low-risk group not receiving APT (non-APT). Bleeding complications (BC) and thromboembolic complications (TC) were assessed. Perioperative and outcome variables in groups receiving APT were compared with those in the non-APT group. RESULTS: APT-HR, APT-LR, and non-APT groups included 54 (9.3%), 114 (19.7%), and 410 (70.9%) patients, respectively. Blood loss during operation (p = 0.304), operative time (p = 0.956), hospitalisation after surgery (p = 0.307), and Clavien–Dindo classification of surgery-related complications (p = 0.467) were not significantly different in the three groups. Occurrence of intra-operative BC (blood loss ≥ 200 ml) (p = 0.864), post-operative BC (p = 0.630), and TC (p = 0.287) were also not significantly different in the three groups. Results of our analysis indicated that APT and non-interrupted APT were not associated with BC or TC. CONCLUSIONS: Analysis of laparoscopic colorectal resection in CRC showed that APT was not a major factor for fatal BC or TC. In patients with high thromboembolic risk, continuing aspirin may inhibit the increase in TC without increasing BC in the peri-operative period. BioMed Central 2019-06-01 /pmc/articles/PMC6545215/ /pubmed/31153382 http://dx.doi.org/10.1186/s12957-019-1634-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yoshimoto, Yasunori
Fujikawa, Takahisa
Tanaka, Akira
Hayashi, Hideto
Shimoike, Norihiro
Kawamoto, Hiroshi
Nakasuga, Chiyo
Yamamoto, Tsunenori
Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection
title Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection
title_full Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection
title_fullStr Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection
title_full_unstemmed Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection
title_short Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection
title_sort optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545215/
https://www.ncbi.nlm.nih.gov/pubmed/31153382
http://dx.doi.org/10.1186/s12957-019-1634-4
work_keys_str_mv AT yoshimotoyasunori optimaluseofantiplateletagentsespeciallyaspirinintheperioperativemanagementofcolorectalcancerpatientsundergoinglaparoscopiccolorectalresection
AT fujikawatakahisa optimaluseofantiplateletagentsespeciallyaspirinintheperioperativemanagementofcolorectalcancerpatientsundergoinglaparoscopiccolorectalresection
AT tanakaakira optimaluseofantiplateletagentsespeciallyaspirinintheperioperativemanagementofcolorectalcancerpatientsundergoinglaparoscopiccolorectalresection
AT hayashihideto optimaluseofantiplateletagentsespeciallyaspirinintheperioperativemanagementofcolorectalcancerpatientsundergoinglaparoscopiccolorectalresection
AT shimoikenorihiro optimaluseofantiplateletagentsespeciallyaspirinintheperioperativemanagementofcolorectalcancerpatientsundergoinglaparoscopiccolorectalresection
AT kawamotohiroshi optimaluseofantiplateletagentsespeciallyaspirinintheperioperativemanagementofcolorectalcancerpatientsundergoinglaparoscopiccolorectalresection
AT nakasugachiyo optimaluseofantiplateletagentsespeciallyaspirinintheperioperativemanagementofcolorectalcancerpatientsundergoinglaparoscopiccolorectalresection
AT yamamototsunenori optimaluseofantiplateletagentsespeciallyaspirinintheperioperativemanagementofcolorectalcancerpatientsundergoinglaparoscopiccolorectalresection